BioAdaptives Unveils Xcellara Platform Strategy Ahead of XcellaraHeart Launch

BioAdaptives (OTC: BDPT) has unveiled the scientific strategy behind its Xcellara™ cellular wellness platform, setting the stage for the Aug. 1 commercial launch of XcellaraHeart™. The platform is built on a stem/progenitor cell mobilization base, supported by a human randomized controlled trial that demonstrated an average 268.8% increase in circulating stem/progenitor-type cells. This base is combined with tissue-specific ingredients designed to support the body’s natural signaling pathways and direct those cells to targeted areas. The first commercial application, XcellaraHeart, pairs the Xcellara base with Tanshinone IIA, a compound derived from Danshen, which has been studied for its role in cardiovascular SDF-1α/CXCR4 signaling.

BioAdaptives plans to expand the platform with additional formulas targeting wellness categories such as joint mobility, skin health, cognitive wellness, and metabolic resilience, all using the same supply-and-direction development model. The company's flagship Xcellara base formula is the only dietary supplement with a human randomized, double-blind, placebo-controlled clinical trial showing a 268.8% increase in circulating hematopoietic stem and progenitor cells at four weeks, with zero adverse effects on more than twenty blood parameters. The complete scientific evidence dossier for XcellaraHeart will be available at products.xcellara.com/science, separating what has been demonstrated in BioAdaptives’ human clinical research from published research on Tanshinone IIA and the company’s product-development rationale.

BioAdaptives Inc., developer of the Xcellara line, is positioning itself at the forefront of cellular wellness supplements. The news was disseminated by BioMedWire, a specialized communications platform focused on the Biotechnology, Biomedical Sciences, and Life Sciences sectors, and part of the Dynamic Brand Portfolio @ IBN. For more information, visit BioMedWire.